Search

AbCellera Biologics Inc

Closed

SectorHealthcare

12.38 1.23

Overview

Share price change

24h

Current

Min

12.04

Max

12.49

Key metrics

By Trading Economics

Income

-55M

-99M

Sales

-4.3M

4.1M

EPS

-0.18

Profit margin

-2,434.37

Employees

562

EBITDA

-645K

-42M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+37.36% upside

Dividends

By Acuity

Next Earnings

5 lis 2026

Market Stats

By TradingEconomics

Market Cap

1.9B

3.7B

Previous open

11.15

Previous close

12.38

News Sentiment

By Acuity

50%

50%

160 / 340 Ranking in Healthcare

AbCellera Biologics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 sie 2026, 19:56 UTC

Correlated Moves

Abcellera Biologics Inc shares are lower today, influenced by declines in the ARK Genomic Revolution ETF and broader genomic sector trends.

25 sie 2026, 23:06 UTC

Abcellera Biologics Inc. shares declined slightly in after-market trading, despite remaining above their 20-day moving average after recent gains.

24 sie 2026, 23:36 UTC

Social Media

Abcellera Biologics Inc. is rising in after-market trading, fueled by a director's $570,000 insider purchase near its 52-week high, indicating insider confidence.

21 sie 2026, 19:36 UTC

Social Media
Correlated Moves

Abcellera Biologics Inc shares are lower today amid broader market pressures. The decline coincides with a drop in U.S. Treasury yields and infrastructure-related assets.

20 sie 2026, 19:16 UTC

Social Media
Correlated Moves

Abcellera shares lower amid broader market pressures, influenced by SPDR ETF.

19 sie 2026, 23:02 UTC

Social Media

Abcellera Biologics Inc shares are higher in after-hours trading, reflecting increased investor interest and social media discussions about the stock's potential at $12.20.

18 sie 2026, 19:56 UTC

Correlated Moves

Abcellera Biologics Inc shares are lower, influenced by declines in small-cap stocks and rising Treasury yields amid ongoing inflation concerns.

17 sie 2026, 23:06 UTC

Correlated Moves

Abcellera Biologics Inc shares are lower in after-market trading, following unusual volatility and a decline in the Russell 2000 Index.

14 sie 2026, 19:44 UTC

Social Media
News

Abcellera Biologics Inc shares are higher today amid increased call option volume and discussions of insider buying, with the stock trading around $10.50.

13 sie 2026, 19:31 UTC

Social Media
News

Abcellera Biologics priced an oversubscribed offering at $9.75 per share, aiming to raise $200 million. Shares are higher since Wednesday's close despite earlier pullback.

12 sie 2026, 20:02 UTC

Social Media
News

Abcellera Biologics has launched a $200 million public offering to support its lead program, while shares are advancing during today's trading session.

11 sie 2026, 22:51 UTC

News

Abcellera Biologics announced a $200 million public offering, contributing to a decline in after-market trading amid investor concerns over potential dilution.

10 sie 2026, 23:06 UTC

Correlated Moves
Event
News
Social Media

Abcellera Biologics reported positive Phase 2 trial results for ABCL635, but shares are lower in after-market hours amid broader market declines.

8 sie 2026, 00:06 UTC

Event
News

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are trading higher in after-market hours.

7 sie 2026, 23:21 UTC

Social Media
News
Event

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

6 sie 2026, 23:06 UTC

Abcellera Biologics Inc. shares are lower in after-market trading, despite earlier reaching a session high and remaining above the 20-day moving average.

5 sie 2026, 23:02 UTC

Social Media
News

Abcellera Biologics shares are lower in after-market hours following disappointing Q2 results, with an EPS of -$0.18 and revenue of $4.1 million.

3 sie 2026, 19:36 UTC

Correlated Moves

Abcellera Biologics Inc shares are higher as market sentiment improves following President Trump's cancellation of a military strike on Iran.

31 lip 2026, 19:33 UTC

Correlated Moves
Social Media

Abcellera Biologics Inc is declining during Friday's session, reflecting broader biotech sector weakness amid rising yields and inflation concerns.

30 lip 2026, 23:41 UTC

Correlated Moves

Abcellera Biologics shares are lower in after-market trading, reflecting broader market volatility following the Federal Reserve's decision to maintain interest rates.

29 lip 2026, 23:51 UTC

Abcellera Biologics Inc. shares were roughly flat in after-market hours, with no specific news identified. The stock is down significantly from last month's close.

28 lip 2026, 19:41 UTC

News

Abcellera Biologics is rising, driven by gains in the Life Sciences Tools & Services sector and positive trends in the antibody therapeutics market.

27 lip 2026, 19:46 UTC

Correlated Moves

Abcellera Biologics Inc shares are higher, reflecting a modest increase since Friday's close. Broader market gains may influence sentiment in life sciences.

24 lip 2026, 23:46 UTC

Abcellera Biologics Inc shares are higher in after-market hours, showing resilience despite recent challenges in the bond market and declining prices.

22 lip 2026, 20:06 UTC

Abcellera Biologics Inc shares are lower today, reflecting broader market trends amid uncertainty ahead of the Federal Reserve meeting on July 29.

21 lip 2026, 23:06 UTC

Correlated Moves

Abcellera Biologics shares higher in after-market trading, maintaining strong performance since Tuesday's close, despite being below its 20-day moving average.

20 lip 2026, 23:16 UTC

Abcellera Biologics Inc. shares are roughly flat in after-market trading, remaining about 16.33% below their 20-day moving average.

Peer Comparison

Price change

AbCellera Biologics Inc Forecast

Price Target

By TipRanks

37.36% upside

12 Months Forecast

Average 17.17 USD  37.36%

High 30 USD

Low 9 USD

Based on 7 Wall Street analysts offering 12 month price targets forAbCellera Biologics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Sentiment

By Acuity

160 / 340 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
help-icon Live chat